RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

Business Wire • Feb 5, 2026

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights

GlobeNewsWire • Jan 27, 2026

GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.

Zacks Investment Research • Jan 21, 2026

GSK to buy RAPT Therapeutics for $2.2 billion

GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.

Reuters • Jan 20, 2026

RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition

Shares of RAPT Therapeutics surged sharply on Tuesday after the biopharmaceutical company said it had agreed to be acquired by British drugmaker GSK in a deal valued at about $2.2 billion, giving the larger group access to a late-stage food allergy treatment. RAPT stock jumped 64% to $57.

Invezz • Jan 20, 2026

Why Rapt Therapeutics Stock Soared Today

GSK offered to buy Rapt Therapeutics for a sizable premium to its recent market value. Rapt's experimental antibody therapy could help millions of people who suffer from severe food allergies.

The Motley Fool • Jan 20, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc.

PRNewsWire • Jan 20, 2026

Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Jan. 20, 2026 /PRNewswire/ -- Ademi LLP is investigating RAPT (NASDAQ: RAPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Jan 20, 2026

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.

Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.

Barrons • Jan 20, 2026

RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halper Sadeh encourages RAPT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether RAPT and its board of directors.

Business Wire • Jan 20, 2026